Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
复制标题
基于白细胞介素 2 的免疫疗法和化学免疫疗法治疗转移性黑色素瘤。
DOI：
10.1007/978-3-642-78771-3_29
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
W. Hunstein
中科院分区：
文献类型：
--
作者：
Ulrich Keilholz;C. Scheibenbogen;P. Brossart;T. Möhler;Wolfgang Tilgen;W. Hunstein
本文总结了免疫疗法和化学免疫疗法治疗晚期黑色素瘤的经验。共有45名患者最初接受了α干扰素（IFN α）和高剂量白细胞介素-2（IL-2）递减方案的免疫治疗。客观缓解率为31%，另有36%为混合缓解（MR）和疾病稳定（SD）。共有18例IFN-α/IL-2免疫治疗失败的患者接受了达卡巴辛（DTIC）的后续化疗，随后是IFN-α。该二线方案的应答率为22%。另外11名IFN-α/IL-2失败的患者在第1天接受单剂量DTIC或顺铂（CDDP），随后根据与先前相同的方案接受IFN-α/IL-2，不进行化疗。DTIC或CDDP的添加耐受性相当好。次级介质的诱导未被抑制，表明IL-2介导的免疫效应未受损。目前正在进行一项随机临床试验，以比较联合免疫疗法与单独免疫疗法。
This report summarizes our experience in the treatment of advanced melanoma with immunotherapy and chemoimmunotherapy. A total of 45 patients initially received immunotherapy with interferon-alpha (IFN alpha) and a decrescendo regimen of high-dose interleukin-2 (IL-2). The objective response rate is 31% with an additional 36% of mixed response (MR) and stable disease (SD). A total of 18 patients failing immunotherapy with IFN-alpha/IL-2 received subsequent chemotherapy with dacarbacine (DTIC), followed by IFN-alpha. The response rate for this second-line regimen is 22%. A further 11 patients failing IFN-alpha/IL-2 received a single dose of DTIC or cisplatinum (CDDP) on day 1, followed by IFN-alpha/IL-2 according to the same protocol as previously, without chemotherapy. The addition of DTIC or CDDP was fairly well tolerated. Induction of secondary mediators was not inhibited, suggesting that the immunologic effects mediated by IL-2 are not impaired. A randomized clinical trial is now being performed to compare combined chemoimmunotherapy with immunotherapy alone.